Evidence map›Paper›PMID 21170264›Full record

ArticleNeoplasia (New York, N.Y.)2010

Identification of a preneoplastic gene expression profile in tubal epithelium of BRCA1 mutation carriers.

Joshua Z Press, Kaitlyn Wurz, Barbara M Norquist, Ming K Lee, Christopher Pennil, Rochelle Garcia, Piri Welcsh, Barbara A Goff, Elizabeth M Swisher

Open access · goldAbstract read
In one paragraph

Article in Neoplasia (New York, N.Y.), 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
3.2field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 25 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. New Predictive Biomarkers for Ovarian Cancer.Diagnostics (Basel, Switzerland) · 2021
    Review
  6. Review
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. The interconnectedness of cancer cell signaling.Neoplasia (New York, N.Y.) · 2011
    Article
  15. Review
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Joshua Z PressDivision of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Washington School of Medicine, Seattle, WA 98195, USA. jzp@u.washington.edu
Kaitlyn Wurz
Barbara M Norquist
Ming K Lee
Christopher Pennil
Rochelle Garcia
Piri Welcsh
Barbara A Goff
Elizabeth M Swisher
University of Washington · USUniversity of Washington Medical Center · US

Funding

Defining a Pre-Malignant Phenotype in Fallopian Tube EpitheliumR01CA131965 · NCI · UNIVERSITY OF WASHINGTON · PI SWISHER, ELIZABETH MARY · 2009 to 2013
$1.6M
NCI NIH HHS 1R01CA131965NCI NIH HHS R01 CA131965
6 · The paper itself

Abstract

Microinvasive carcinomas and high-grade intraepithelial neoplasms are commonly discovered within the fallopian tube of BRCA1 mutation carriers at the time of risk-reducing salpingo-oophorectomy, suggesting that many BRCA1-mutated ovarian carcinomas originate in tubal epithelium. We hypothesized that changes in gene expression profiles within the histologically normal fallopian tube epithelium of BRCA1 mutation carriers would overlap with the expression profiles in BRCA1-mutated ovarian carcinomas and represent a BRCA1 preneoplastic signature. Laser capture microdissection of frozen sections was used to isolate neoplastic cells or histologically normal fallopian tube epithelium, and expression profiles were generated on Affymetrix U133 Plus 2.0 gene expression arrays. Normal-risk controls were 11 women wild type for BRCA1 and BRCA2 (WT-FT). WT-FT were compared with histologically normal fallopian tube epithelium from seven women with deleterious BRCA1 mutations who had foci of at least intraepithelial neoplasm within their fallopian tube (B1-FTocc). WT-FT samples were also compared with 12 BRCA1 ovarian carcinomas (B1-CA). The comparison of WT-FT versus B1-FTocc resulted in 152 differentially expressed probe sets, and the comparison of WT-FT versus B1-CA resulted in 4079 differentially expressed probe sets. The BRCA1 preneoplastic signature was composed of the overlap between these two lists, which included 41 concordant probe sets. Genes in the BRCA1 preneoplastic signature included several known tumor suppressor genes such as CDKN1C and EFEMP1 and several thought to be important in invasion and metastasis such as E2F3. The expression of a subset of genes was validated with quantitative reverse transcription-polymerase chain reaction and immunohistochemistry.

Indexed as

Gene Expression ProfilingGenes, BRCA1Genes, Tumor SuppressorCarcinoma, Ovarian EpithelialCyclin-Dependent Kinase Inhibitor p57E2F3 Transcription FactorEpitheliumExtracellular Matrix ProteinsFallopian Tube NeoplasmsFallopian TubesFemaleFluorescent Antibody TechniqueGenes, BRCA2Genetic Predisposition to DiseaseHumansKi-67 AntigenCDKN1C protein, humanCyclin-Dependent Kinase Inhibitor p57E2F3 protein, humanE2F3 Transcription FactorEFEMP1 protein, humanExtracellular Matrix ProteinsKi-67 Antigen

Identifiers

PMID21170264
PMCPMC3003134
OpenAlexW2122950718

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.